| Severity | Code | Message |
|---|---|---|
| WARNING | message:equ_Continuing_and_discontinued_operations_CashFlowsFromUsedInOperatingActivitiesContinuingOperations | Reported values for alternative tagging of same economic concept are not equal |
| WARNING | message:equ_Continuing_and_discontinued_operations_CashFlowsFromUsedInOperatingActivitiesContinuingOperations | Reported values for alternative tagging of same economic concept are not equal |
| WARNING | message:equ_Continuing_and_discontinued_operations_CashFlowsFromUsedInOperatingActivitiesContinuingOperations | Reported values for alternative tagging of same economic concept are not equal |
| WARNING | message:equ_Continuing_and_discontinued_operations_CashFlowsFromUsedInInvestingActivitiesContinuingOperations | Reported values for alternative tagging of same economic concept are not equal |
| WARNING | message:equ_Continuing_and_discontinued_operations_CashFlowsFromUsedInInvestingActivitiesContinuingOperations | Reported values for alternative tagging of same economic concept are not equal |
| WARNING | message:equ_Continuing_and_discontinued_operations_CashFlowsFromUsedInInvestingActivitiesContinuingOperations | Reported values for alternative tagging of same economic concept are not equal |
| WARNING | message:positive | Reported value is below 0 |
| WARNING | message:equ_Continuing_and_discontinued_operations_CashFlowsFromUsedInFinancingActivitiesContinuingOperations | Reported values for alternative tagging of same economic concept are not equal |
| WARNING | message:equ_Continuing_and_discontinued_operations_CashFlowsFromUsedInFinancingActivitiesContinuingOperations | Reported values for alternative tagging of same economic concept are not equal |
| WARNING | message:equ_Continuing_and_discontinued_operations_CashFlowsFromUsedInFinancingActivitiesContinuingOperations | Reported values for alternative tagging of same economic concept are not equal |
| WARNING | message:tech_duplicated_facts1 | Duplicated facts with different values have been reported for: ix:nonNumeric, value:<div class="positionStyle-6163b486fbe6"><div style="width: 489pt;"><div class="positionStyle-36d194b72471 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-e4354d28"><span class="positionStyle-b58d73c6e12d" style="width: 4.15pt;">(1)<span style="display: inline-block; height: 3.6399999999999997pt; width: 7.19pt;"></span></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 331.26pt;">Cette section permet de répondre au point de donnée [ESRS E1, E1-9 Para. 15] inclus dans la section « <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-931a689d497e" style="width: 147.06pt;">3.2.1.1. Stratégie climatique et gestion des IRO<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-ebe41e51ce20" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-d50f7f979a73 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 49.87pt;">correspondants<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-0c2fabeb8813" style="width: 7.69pt;"> ».<span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div> != <div class="positionStyle-377865f74454 sizeStyle-d24d8708" style="font-size: 12pt;"><span class="fidelity charStyle-26704b54 positionStyle-359429408c7f">D.5. Dépréciation des actifs incorporels et corporels <span style="display: inline-block; height: 9.6pt;"></span><span id="i7040df97782241f8a893914bfe366ce3"></span></span><span class="fidelity charStyle-fdc4e8ce positionStyle-14dec09bbe82">(1)<span style="display: inline-block; height: 6.24pt;"></span></span></div><div class="positionStyle-673b27a2db14 sizeStyle-d24d8708" style="font-size: 12pt;"><span class="fidelity charStyle-449e0599 positionStyle-359429408c7f">Écart d’acquisition<span style="display: inline-block; height: 8pt;"></span><span id="ia40ceeeb259c435fbefa90176c758481"></span></span></div><div class="positionStyle-3928cb82d3ef sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.84pt;">Dans le cadre du test annuel de dépréciation de l’écart d’acquisition, la valeur recouvrable est déterminée pour le segment<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-adb79b8db2ca" style="width: 1.95pt;"> <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-68a9f79d03ff sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.82pt;">Biopharma sur la base de la valeur d’utilité fondée sur l’actualisation des flux futurs de trésorerie estimés, en application des<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-e8b93dfd3c8c" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-ae2c8d88fb08 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 131.98pt;">principes décrits dans la note B.6.1.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-47fed9c7c6c0 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.7pt;">La valeur d’utilité du segment Biopharma a été déterminée en utilisant un taux d’actualisation après impôts, appliqué à des flux<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-edf382f9d289" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-30a5db3a11f5 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 156.47pt;">futurs de trésorerie estimés après impôts.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-908244daa97d sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 198.06pt;">Le taux utilisé pour le test de dépréciation réalisé en <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-9795a4fef152" style="width: 20.13pt;">2024<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-f8f41e1bb9cb" style="width: 29.56pt;"> s’élève <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-6263bea74e1b" style="width: 6.44pt;">à <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-5114f929f45a" style="width: 24.54pt;">7,25 %<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-58e7b490ccc2" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-cf0d572fe7c9" style="width: 106.84pt;">pour le segment Biopharma.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-d01fd4239007 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.87pt;">Le taux d’actualisation avant impôts appliqué sur des flux de trésorerie estimés avant impôts est calculé sur la base d’un<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-c9cdbc837af6" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-5d64d695b878 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 314.19pt;">processus itératif à partir de la valeur d’utilité préalablement déterminée. Il s’élève à<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-fc442288a5db" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-fc80869adc62" style="width: 20.71pt;">9,8 %<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-ca1404cc59f0" style="width: 7.05pt;"> p<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-3038c38df6b8" style="width: 58.36pt;">our le segment <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-cbe4088d positionStyle-71716ea51b23" style="width: 43.38pt;"><span style="background-color: inherit;">Biopharma.</span><span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-f56070d26abd sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.74pt;">Les hypothèses utilisées pour le test de dépréciation de l'écart d’acquisition sont revues annuellement. Outre le taux<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-97a9229c706d" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-0a852e8fd4a5 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 204.01pt;">d’actualisation, les principales hypothèses utilisées en <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-ffd4131bb1bf" style="width: 20.13pt;">2024<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-8ab876615271" style="width: 72.33pt;"> sont les suivantes :<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-28e1999794c2 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 230.29pt;">le taux de croissance à l’infini des flux futurs de trésorerie est <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-80cb8603e9d8" style="width: 13.41pt;">nul <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-85f545fc1da1" style="width: 108.79pt;">pour le segment Biopharma ;<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-51947483acd4" style="width: 1.95pt;"> <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-67f62a643387 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.43pt;">Sanofi s’appuie également sur des hypothèses relatives à la probabilité de succès de ses projets de recherche et<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-8458a1a7faba" style="width: 1.95pt;"> <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-00805e1b0f4a sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 407.23pt;">développement en cours et plus généralement à sa capacité à renouveler son portefeuille à plus long terme.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-525d4bd02ea1 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.75pt;">Une comparaison entre la valeur d’utilité ainsi déterminée et la valeur nette au bilan est effectuée et fait l’objet d’analyses de<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-6ce548f1d13b" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-3c3437cf650b sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 221.67pt;">sensibilité en fonction des principaux paramètres incluant :<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-e5e4eaa20fe5 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 129.98pt;">l’évolution du taux d’actualisation ;<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-79a9e1ef1c61 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 167.12pt;">l’évolution du taux de croissance à l’infini ; et<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-4ef7eafb0ef0 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 165.81pt;">l’évolution du taux de marge opérationnelle.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-c981ddbb8aed sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.79pt;">Aucune dépréciation de l'écart d’acquisition testé ne serait à constater en cas d’évolution raisonnablement possible des<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-f3d00783b17f" style="width: 1.95pt;"> <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-d3d92bf603d1 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 89.8pt;">hypothèses utilisées en <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-861c9a431090" style="width: 20.13pt;">2024<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-35ec47ca2bb0" style="width: 1.99pt;">.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-c56f7fd4ef17 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 332.12pt;">Aucune dépréciation n’a été constatée sur les écarts d’acquisition au titre des exercices <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b784274b298b" style="width: 20.13pt;">2024<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-37e3bf9f6df2" style="width: 3.94pt;">, <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-59430056abe4" style="width: 19.86pt;">2023<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-81ab899e79f9" style="width: 11.73pt;"> et <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-dbb2687581ce" style="width: 19.75pt;">2022<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-6bfeb0c49ca3" style="width: 1.99pt;">.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-faf7ad67cbab sizeStyle-d24d8708" style="font-size: 12pt;"><span class="fidelity charStyle-449e0599 positionStyle-359429408c7f">Autres actifs incorporels<span style="display: inline-block; height: 8pt;"></span><span id="ia396492aecb8428b9adf94e25c90cfc6"></span></span></div><div class="positionStyle-0ac6672e5bcc sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.78pt;">Quand un indicateur de dépréciation a été identifié pour un actif, un calcul de la valeur d’utilité est effectué, fondé sur les<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-ba26ae2e4557" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-2190e226507d sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.86pt;">prévisions de flux futurs de trésorerie après impôts de cet actif actualisés avec un taux après impôts. Dans le cadre des tests de<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-7987d75c6f28" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-4f883fef7fef sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.73pt;">dépréciation, les flux financiers d’impôts liés à cet actif sont déterminés en fonction d’un taux notionnel d’impôts, qui intègre<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-a3a6a2e27b8e" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-8ff652f42fce sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.73pt;">l’avantage fiscal notionnel qui résulterait de l’amortissement de cet actif incorporel en considérant sa valeur d’utilité comme sa<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-a3a6a2e27b8e" style="width: 1.95pt;"> <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-7ae7d16e2cc0 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.72pt;">base fiscale amortissable. L’utilisation de taux d’actualisation après impôts appliqués à des flux de trésorerie après impôts conduit<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-268e076fc9e6" style="width: 1.95pt;"> <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-9ec990d86568 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.71pt;">à la détermination de valeurs d’utilité identiques à celles obtenues en utilisant des taux avant impôts appliqués à des flux de<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-a2dd07f22b42" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-8c3cab5a0d58 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 90.61pt;">trésorerie non fiscalisés.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-c004e188cc5d sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 188.43pt;">Les taux d’actualisation après impôts utilisés en <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-0d8b50eae990" style="width: 20.13pt;">2024<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-d3de993bed43" style="width: 281.2pt;"> pour les tests des autres actifs incorporels sont dérivés du coût moyen<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b0eda31a39ad" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-e611ed40eee1 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.76pt;">pondéré du capital de Sanofi et ajustés en fonction des risques spécifiques des pays et des activités, représentant des taux<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b0eda31a39ad" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-762c8fab7cb9 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 160.47pt;">d’actualisation après impôts compris entre<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-917b537f3134" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-f9848803192b" style="width: 24.54pt;">7,25 %<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-466bb7e30e2b" style="width: 11.73pt;"> et <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-511f7036b347" style="width: 25.2pt;">8,25 %<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-488da7e2e012" style="width: 1.99pt;">.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div><div class="positionStyle-86dd0b40af6c sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.85pt;">Dans la plupart des cas, il n’existe pas de données de marché permettant de déterminer la juste valeur nette des frais de cession<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-f0df506b3533" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-f45ee1c1b8e1 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.81pt;">autrement que par la réalisation d'une estimation similaire des flux futurs de trésorerie. Par conséquent, la valeur recouvrable est<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-6f03bf04cd80" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-3c7ad64cf834 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.75pt;">en substance égale à la valeur d’utilité. Les estimations utilisées pour déterminer la valeur d’utilité sont sensibles aux hypothèses<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-6ce548f1d13b" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-6b30290dfcb2 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.84pt;">spécifiques à la nature de l’actif et aux activités de Sanofi. Hormis le taux d’actualisation, les principales hypothèses utilisées<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-adb79b8db2ca" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-b82829080627 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 11.48pt;">en <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-10fe781007a0" style="width: 20.13pt;">2024<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-cca757120b7f" style="width: 48.15pt;"> portent sur :<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-32c2198a842d sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 141.64pt;">les prévisions à moyen et long terme ;<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-435836fe79e7 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 233.98pt;">les taux de croissance à l’infini ou d’attrition le cas échéant ; et<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-249a56ac7ceb sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 293.62pt;">la probabilité de succès des projets de recherche et développement en cours.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-a0df64a81e48 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 477.91pt;">Les hypothèses utilisées pour la réalisation des tests de dépréciation des actifs incorporels sont revues au moins annuellement.<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-d8d52527996b sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 83.41pt;">Au titre des exercices <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-31db6cec96b3" style="width: 19.75pt;">2022<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-45b234153b5e" style="width: 8.57pt;"> à <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-815eaa0c6462" style="width: 20.13pt;">2024<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-2b6b07b75f27" style="width: 357.87pt;">, les résultats des tests de dépréciation des autres actifs incorporels (hors logiciels) ont conduit<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-a3a6a2e27b8e" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-27984b5b44ad sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 183.72pt;">à enregistrer les dépréciations nettes suivantes<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-d6cdbf736f5e" style="width: 306.08pt;"> (le tableau présente sur l'ensemble des périodes l'ensemble des dépréciations<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b4332b3a566c" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-2417d5e9c56b sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 24.27pt;">nettes<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-e035806b39ef" style="width: 164.92pt;"> du périmètre du Groupe y compris Opella) :<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-b5785da03df5 sizeStyle-d24d8708" style="text-align: justify; text-align-last: var(--justify);"><div class="sizeStyle-616d3a2f wrapperStyle-73a0c67b positionStyle-707305367927"><div><table style="border-collapse: collapse; display: inline-table; font-size: initial; padding: 0; table-layout: fixed; width: 100%;"><tbody><tr style="height: 0;"><td colspan="1" rowspan="1" style="padding: 0; width: 280.5pt;"></td><td colspan="1" rowspan="1" style="padding: 0; width: 69.75pt;"></td><td colspan="1" rowspan="1" style="padding: 0; width: 69.75pt;"></td><td colspan="1" rowspan="1" style="padding: 0; width: 69.75pt;"></td></tr><tr style="height: 12.75pt;"><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-60518f7f69ad sizeStyle-72f36bb9"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-0f056a23"><span class="fidelity charStyle-0bc45b3b positionStyle-401731c6bffc">(en millions d’euros)<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="background-color: #e7e7e8; border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-ee88eebb5c11 sizeStyle-14da2a89"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-8f888f17"><span class="fidelity charStyle-748c885f positionStyle-bf75fd866d18">2024<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-01c178433f67 sizeStyle-14da2a89"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-8f888f17"><span class="fidelity charStyle-748c885f positionStyle-e68b04e2dd04">2023<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-d14f86ed5dba sizeStyle-14da2a89"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-8f888f17"><span class="fidelity charStyle-748c885f positionStyle-94400a8bce7e">2022<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td></tr><tr style="height: 12.75pt;"><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-653232dc9838 sizeStyle-72f36bb9"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-0f056a23"><span class="fidelity charStyle-748c885f positionStyle-401731c6bffc">Dépréciations nettes des reprises sur autres actifs incorporels (hors logiciels)<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="background-color: #e7e7e8; border-bottom: 0.5pt solid #23004c; border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-f1a731c8e8ae sizeStyle-14da2a89"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-8f888f17"><span class="fidelity charStyle-748c885f"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 51.63pt;"></span></span><span class="positionStyle-78a196be88ce">265<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-66d8b00147f1 sizeStyle-14da2a89"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-8f888f17"><span class="fidelity charStyle-748c885f"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 51.81pt;"></span></span><span class="positionStyle-90463c7dad1c">932<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-4cd1de1dd8c2 sizeStyle-14da2a89"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-8f888f17"><span class="fidelity charStyle-748c885f"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 49.09pt;"></span></span><span class="positionStyle-59e754313d11">(454)<span style="display: inline-block; height: 5.6pt;"></span></span></span></div></div></div></td></tr><tr style="height: 12pt;"><td colspan="1" rowspan="1" style="border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-1e2ac2c8d613 sizeStyle-c067d249"><div><div class="positionStyle-83963ec70848 sizeStyle-0f056a23"><span class="fidelity charStyle-0bc45b3b positionStyle-401731c6bffc">Produits commercialisés<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="background-color: #e7e7e8; border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-e46cecd7a633 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 51.94pt;"></span></span><span class="positionStyle-728ce798f3b0">(167)<span style="display: inline-block; height: 5.6pt; width: 0.11pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-9abc1db9c149 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 57.15pt;"></span></span><span class="positionStyle-82cfb5d98e52">—<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-3fea055f5bf0 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 47.77pt;"></span></span><span class="positionStyle-50593a4b0d43">(1 561)<span style="display: inline-block; height: 5.6pt; width: 0.11pt;"></span></span></span></div></div></div></td></tr><tr style="height: 12pt;"><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-30d7c68b7f73 sizeStyle-c067d249"><div><div class="positionStyle-83963ec70848 sizeStyle-0f056a23"><span class="fidelity charStyle-e377bace positionStyle-b3b2997de1f2">Biopharma <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-9fa74a88 positionStyle-e9a3c23866a6">(a)<span style="display: inline-block; height: 3.6399999999999997pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="background-color: #e7e7e8; padding: 0;"><div class="positionStyle-ca0710eda980 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-c27d5888"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 51.94pt;"></span></span><span class="positionStyle-728ce798f3b0">(167)<span style="display: inline-block; height: 5.6pt; width: 0.11pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-a819b1efadc0 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-c27d5888"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 57.15pt;"></span></span><span class="positionStyle-82cfb5d98e52">—<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-3073f2e1c094 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-c27d5888"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 46.06pt;"></span></span><span class="positionStyle-eaa544343dd3">(1 526)<span style="display: inline-block; height: 5.6pt; width: 0.11pt;"></span></span></span></div></div></div></td></tr><tr style="height: 12pt;"><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-1f50fc613f64 sizeStyle-c067d249"><div><div class="positionStyle-83963ec70848 sizeStyle-0f056a23"><span class="fidelity charStyle-e377bace positionStyle-b3b2997de1f2">Opella<span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="background-color: #e7e7e8; padding: 0;"><div class="positionStyle-8d49f88e3f14 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-c27d5888"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 57.15pt;"></span></span><span class="positionStyle-82cfb5d98e52">—<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-3a188f3588f6 sizeStyle-577d904f"><div><div class="positionStyle-90a57c581c95 sizeStyle-8f888f17"><span class="fidelity charStyle-c27d5888"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 57.15pt;"></span></span><span class="positionStyle-82cfb5d98e52">—<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-0061fa649a33 sizeStyle-577d904f"><div><div class="positionStyle-90a57c581c95 sizeStyle-8f888f17"><span class="fidelity charStyle-c27d5888"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 54pt;"></span></span><span class="positionStyle-297cdbd2c11c">(35)<span style="display: inline-block; height: 5.6pt; width: 0.11pt;"></span></span></span></div></div></div></td></tr><tr style="height: 12pt;"><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-12e90b30311d sizeStyle-c067d249"><div><div class="positionStyle-83963ec70848 sizeStyle-0f056a23"><span class="fidelity charStyle-956c0b7b positionStyle-401731c6bffc">Projets de recherche et développement et Plateformes technologiques <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-3c231de9 positionStyle-e78e34a121ff">(b) (c) (d)<span style="display: inline-block; height: 3.6399999999999997pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="background-color: #e7e7e8; padding: 0;"><div class="positionStyle-28985a8a9279 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 53.71pt;"></span></span><span class="positionStyle-a250c731234c">415<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-7dd621f5b9b4 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 51.45pt;"></span></span><span class="positionStyle-1ff4d0569714">896<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-0351c91eabe5 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 49.9pt;"></span></span><span class="positionStyle-eaacfd769d5c">1 107<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td></tr><tr style="height: 12pt;"><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-af6a9f86ba27 sizeStyle-c067d249"><div><div class="positionStyle-83963ec70848 sizeStyle-0f056a23"><span class="fidelity charStyle-956c0b7b positionStyle-401731c6bffc">Autres<span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="background-color: #e7e7e8; border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-7f43ac204972 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 58.29pt;"></span></span><span class="positionStyle-2644f435aa7c">17<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-c433e04e7c4c sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 55.93pt;"></span></span><span class="positionStyle-b98dbe94ff14">36<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-6b13cf4d5140 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 57.15pt;"></span></span><span class="positionStyle-82cfb5d98e52">—<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div class="positionStyle-bc8c6ed1a6f7 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207"><span class="positionStyle-cf2ad5ffba18" style="width: 8.36pt;">(a)<span style="display: inline-block; height: 5.6pt; width: 5.15pt;"></span></span><span class="positionStyle-7aa89c0c0bce" style="width: 224.94pt;">Au 31 décembre 2024, ce montant concerne la reprise d’un montant de <span style="display: inline-block; height: 5.6pt;"></span></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-86be94b77628" style="width: 10.1pt;">167<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-886cc4826366" style="width: 204.94pt;"> millions d’euros constatée dans le cadre de la cession d'Enjaymo.<span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-81c8081c36b5 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-359429408c7f" style="width: 311.99pt;"> Au 31 décembre 2022, ces montants incluent principalement une reprise de dépréciation de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-b2156610c5f7" style="width: 16.77pt;">2 154<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-c169c31f3bd8" style="width: 160.87pt;"> millions d’euros sur les actifs Eloctate et BIVV001<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-ad5cc74ad3d2" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-33da2f2efe8b sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 167.7pt;">appartenant à la franchise Eloctate (respectivement <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-4a42ee88c4b2" style="width: 16.22pt;">1 554<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-35dea5d5f038" style="width: 146.94pt;"> millions d’euros en produits commercialisés et <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-07a79799f3cd" style="width: 13.44pt;">600<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-cdf473e58747" style="width: 134.2pt;"> millions d'euros en projets de recherche et<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-be0d7b939f17" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-07c4d923cd50 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 478.43pt;">développement). En 2019, l’entrée de produits concurrents d’Eloctate avait donné lieu à la mise à jour des perspectives de vente des produits de la<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-8458a1a7faba" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-1797ef14c2b9 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 345.41pt;">franchise et conduit à l’enregistrement d’une perte de valeur des actifs correspondants pour un montant de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-0974604c1dfd" style="width: 9.76pt;">2,8<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-272ec1c7368f" style="width: 123.29pt;"> milliards d’euros. Cette reprise s’inscrit<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-b4332b3a566c" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-151f81e343da sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 478.43pt;">dans le contexte de l’approbation par la FDA, le 22 février 2023, de la demande d’enregistrement d’ALTUVIIIO (nom commercial d’efanesoctocog alpha,<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-8458a1a7faba" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-9738ca91dd73 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 166.5pt;">correspondant au projet BIVV001), déposée en 2022.<span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-4d04ad91f2f8 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207"><span class="positionStyle-359429408c7f" style="width: 8.42pt;">(b)<span style="display: inline-block; height: 5.6pt; width: 2.92pt;"></span></span><span class="positionStyle-4855c92d689a" style="width: 476.12pt;">Au 31 décembre 2024, le suivi des indicateurs de perte de valeur des autres actifs incorporels a conduit à enregistrer une dépréciation nette d’un <span style="display: inline-block; height: 5.6pt; width: 2.38pt;"></span></span></span></div><div class="positionStyle-9ebcbb520b68 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 38.64pt;">montant de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-962e561b427f" style="width: 10.44pt;">415<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-8928235aec6d" style="width: 186.6pt;"> millions d’euros incluant (i) des charges de dépréciation de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-0527b71d4795" style="width: 13.04pt;">640<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-74ab013b560e" style="width: 229.79pt;"> millions d’euros sur divers projets de recherche et développement - dont<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-f0df506b3533" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-06294deff557 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 48.12pt;">une charge de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-ecd4e5719e8b" style="width: 12.11pt;">239<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-4387f16e9f81" style="width: 418.25pt;"> millions d’euros consécutive à la décision d’arrêt de l’essai clinique de phase 3 d’un candidat vaccin contre les souches pathogènes<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-0fbf97140a49" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-f2aaa39566d7 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 334.37pt;">extra-intestinales d’E.coli, intervenue en février 2025 - et (ii) une reprise de dépréciation d’un montant de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-a0e9f22ef824" style="width: 11.84pt;">225<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-d3196036c482" style="width: 132.19pt;"> millions d’euros enregistrée dans le cadre<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-97a9229c706d" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-650493bcf1ae sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 170.96pt;">de la cession de la plateforme technologique ProXTen.<span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-d6008617c9d3 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207"><span class="positionStyle-359429408c7f" style="width: 7.98pt;">(c)<span style="display: inline-block; height: 5.6pt; width: 3.36pt;"></span></span><span class="positionStyle-4855c92d689a" style="width: 263.19pt;">Au 31 décembre 2023, ces montants incluent principalement une dépréciation de <span style="display: inline-block; height: 5.6pt;"></span></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-9d785fbb8fa4" style="width: 12.18pt;">833<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-e19d5d3412b2" style="width: 203.08pt;"> millions d’euros reflétant l’impact de la décision stratégique de<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-f3d00783b17f" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-d0fd3f0f9374 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 464.55pt;">dépriorisation de certains programmes de Recherche et Développement liés notamment aux plateformes technologiques de cellules NK et ProXTen.<span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-7023a022b7e1 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207"><span class="positionStyle-359429408c7f" style="width: 8.42pt;">(d)<span style="display: inline-block; height: 5.6pt; width: 2.92pt;"></span></span><span class="positionStyle-4855c92d689a" style="width: 179.04pt;">Au 31 décembre 2022, ce montant inclut principalement :<span style="display: inline-block; height: 5.6pt;"></span></span></span></div><div class="positionStyle-bb6b0c2730fa sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 117.41pt;">- une dépréciation d'un montant de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-67acc3ee9448" style="width: 16.94pt;">1 586<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-63be32d8499d" style="width: 344.1pt;"> millions d'euros portant sur le projet en développement SAR444245 (interleukine-2 non-alpha), enregistrée<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-f3d00783b17f" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-8ba96848e220 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-f37c12ed05b4" style="width: 435.39pt;">suite à la mise à jour des projections des flux de trésorerie attendus, en raison d'évolutions défavorables de ses perspectives de lancement ;<span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-f707c2670463 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 3.15pt;">-<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-b9bdb0d41cd6" style="width: 91.85pt;"> une reprise d’un montant de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-050fdf2e5865" style="width: 13.44pt;">600<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-1af88aaad23e" style="width: 164.64pt;"> millions d’euros sur le projet BIVV001 (voir ci-dessus)<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-256faca6758c" style="width: 1.65pt;">.<span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-ad832f011bab sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.69pt;">En application de la norme IFRS5, les autres actifs incorporels relatifs à l'activité Opella ont été mesurés conformément à la norme<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-8137a6ec08a7" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-50c12e5bb4bb sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.85pt;">IAS 36 immédiatement avant leur reclassement en actifs destinés à être cédés. Cette évaluation n'a pas conduit à enregistrer de<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-f0df506b3533" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-5ca635bc7f1f sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 146.07pt;">dépréciation de leur valeur comptable.<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-8a97ff64a56c" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-8e2803cf9685 sizeStyle-d24d8708" style="font-size: 12pt;"><span class="fidelity charStyle-449e0599 positionStyle-359429408c7f">Actifs corporels<span style="display: inline-block; height: 8pt;"></span><span id="i7d84e14f5729489d9607060c92453704"></span></span></div><div class="positionStyle-d08736615695 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 319.97pt;">Le montant des dépréciations relatives aux actifs corporels est présenté en note D.3.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-4ff5f516a4d9 sizeStyle-d24d8708" style="font-size: 12pt;"><span class="fidelity charStyle-449e0599 positionStyle-359429408c7f">Risques et opportunités liés au changement climatique<span style="display: inline-block; height: 8pt;"></span><span id="i0fde9098c3434973b0f7e53aebc17b7b"></span></span></div><div class="positionStyle-e7dccf84e0ce sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 110.81pt;">Sanofi a identifié plusieurs <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-27680c46fc98" style="width: 29.62pt;">scenarii<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-c75c9c1d6db8" style="width: 349.4pt;"> plausibles afin de mesurer les risques et opportunités liés au changement climatique<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-48a33b297368" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-dc1081e40091 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 267.66pt;">susceptibles d’impacter les activités du Groupe à moyen et long terme.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-c493724c93b4 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 66.19pt;">Ceux-ci incluent :<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-f383e58d286a sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 15pt;">un <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-2431bf91e24e" style="width: 32.62pt;">scenario<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-ef2696a90e6b" style="width: 112.58pt;"> de remédiation agressive <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-ee27a81ab9c8" style="width: 90.85pt;">(Aggressive Mitigation)<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-1f9dff518f88" style="width: 227.44pt;">, basé sur une collaboration mondiale visant à réduire<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-8e59220fdeb3" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-9a461a7ee8ae sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.42pt;">immédiatement les émissions pour atteindre les objectifs de l’Accord de Paris (limitation du réchauffement à 1,5 °C au-dessus<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b0eda31a39ad" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-3b7c5ca74aba sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 156.72pt;">des niveaux de l’ère préindustrielle). Ce <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-2072efb3c9c4" style="width: 32.62pt;">scenario<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-900e8f880be0" style="width: 289.08pt;">, qui engendre des risques de transition à une économie moins carbonée,<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b0eda31a39ad" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-31aa7b68e6fd sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.47pt;">implique des changements significatifs ayant trait notamment aux politiques, technologies, marchés et aspects juridiques de<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-048c0de60422" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-1b321a58836c sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 306.24pt;">son activité, dans le but d’atteindre ces objectifs de remédiation et d’adaptation ;<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-b166bb766954 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 11.86pt;">un <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-58723037a48e" style="width: 32.62pt;">scenario<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-d8f3aba089ce" style="width: 183.56pt;"> basé sur l’absence d’actions relatives au climat, <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-1935dda104a4" style="width: 70.08pt;">No Climate Action<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-811c8df62802" style="width: 180.34pt;">, conduisant à un réchauffement global de 4 °C<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b4332b3a566c" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-0a75ae8231ae sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.4pt;">au-dessus des niveaux de l’ère préindustrielle en 2100, qui induit des risques physiques ponctuels résultant des modifications<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-97a9229c706d" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-47e2d350715a sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.4pt;">du climat et des évolutions à long terme des tendances climatiques, avec des conséquences financières potentielles résultant<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-97a9229c706d" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-0e4979322276 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.43pt;">des dommages directs aux biens ou des dommages indirects liés à l’interruption des chaînes de distribution logistique, à des<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-8458a1a7faba" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-fea4be371dda sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.46pt;">modifications dans la disponibilité des ressources en eau, dans l’approvisionnement ou la qualités des ressources, dans la<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b4332b3a566c" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-8bc3b01fabe0 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.48pt;">sécurité alimentaire et des modifications des températures extrêmes impactant les installations, les opérations, la distribution,<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-0fbf97140a49" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-ce63b8e42675 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 209.69pt;">les besoins en transport ou la sécurité des employés ; et<span style="display: inline-block; height: 6.8pt;"></span></span></div></div><div class="positionStyle-86dd0b40af6c sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 12.34pt;">un <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-9aa98d16a200" style="width: 32.62pt;">scenario<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-289bae67caa0" style="width: 39.56pt;"> probable <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-29b79a932aad" style="width: 48.4pt;">(Most Likely)<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4373f4c2922e" style="width: 345.49pt;">, incluant des efforts régionaux parcellaires destinés à initier une réduction des émissions,<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-6ce548f1d13b" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-f45ee1c1b8e1 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.46pt;">mais insuffisants pour atteindre les objectifs de l’Accord de Paris (les émissions continuent d’augmenter quoiqu’à un rythme<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b4332b3a566c" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-3c7ad64cf834 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 257pt;">réduit, conduisant à une augmentation des températures de 2,8 °C).<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-012a961a24cb sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.77pt;">L’importance et la probabilité d’occurrence de ces risques ont été mesurés et n’ont pas conduit à identifier d’effets significatifs<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-8458a1a7faba" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-a4f80aaea193 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 289.38pt;">pouvant générer un risque de dépréciation sur les actifs des UGT du Groupe.<span style="display: inline-block; height: 6.8pt;"></span></span></div> please review selected entries. |
| WARNING | message:tech_duplicated_facts1 | Duplicated facts with different values have been reported for: ix:nonNumeric, value:<div class="positionStyle-377865f74454 sizeStyle-d24d8708" style="font-size: 12pt;"><span class="fidelity charStyle-26704b54 positionStyle-359429408c7f">D.5. Dépréciation des actifs incorporels et corporels <span style="display: inline-block; height: 9.6pt;"></span><span id="i7040df97782241f8a893914bfe366ce3"></span></span><span class="fidelity charStyle-fdc4e8ce positionStyle-14dec09bbe82">(1)<span style="display: inline-block; height: 6.24pt;"></span></span></div><div class="positionStyle-673b27a2db14 sizeStyle-d24d8708" style="font-size: 12pt;"><span class="fidelity charStyle-449e0599 positionStyle-359429408c7f">Écart d’acquisition<span style="display: inline-block; height: 8pt;"></span><span id="ia40ceeeb259c435fbefa90176c758481"></span></span></div><div class="positionStyle-3928cb82d3ef sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.84pt;">Dans le cadre du test annuel de dépréciation de l’écart d’acquisition, la valeur recouvrable est déterminée pour le segment<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-adb79b8db2ca" style="width: 1.95pt;"> <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-68a9f79d03ff sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.82pt;">Biopharma sur la base de la valeur d’utilité fondée sur l’actualisation des flux futurs de trésorerie estimés, en application des<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-e8b93dfd3c8c" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-ae2c8d88fb08 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 131.98pt;">principes décrits dans la note B.6.1.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-47fed9c7c6c0 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.7pt;">La valeur d’utilité du segment Biopharma a été déterminée en utilisant un taux d’actualisation après impôts, appliqué à des flux<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-edf382f9d289" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-30a5db3a11f5 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 156.47pt;">futurs de trésorerie estimés après impôts.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-908244daa97d sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 198.06pt;">Le taux utilisé pour le test de dépréciation réalisé en <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-9795a4fef152" style="width: 20.13pt;">2024<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-f8f41e1bb9cb" style="width: 29.56pt;"> s’élève <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-6263bea74e1b" style="width: 6.44pt;">à <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-5114f929f45a" style="width: 24.54pt;">7,25 %<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-58e7b490ccc2" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-cf0d572fe7c9" style="width: 106.84pt;">pour le segment Biopharma.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-d01fd4239007 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.87pt;">Le taux d’actualisation avant impôts appliqué sur des flux de trésorerie estimés avant impôts est calculé sur la base d’un<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-c9cdbc837af6" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-5d64d695b878 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 314.19pt;">processus itératif à partir de la valeur d’utilité préalablement déterminée. Il s’élève à<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-fc442288a5db" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-fc80869adc62" style="width: 20.71pt;">9,8 %<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-ca1404cc59f0" style="width: 7.05pt;"> p<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-3038c38df6b8" style="width: 58.36pt;">our le segment <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-cbe4088d positionStyle-71716ea51b23" style="width: 43.38pt;"><span style="background-color: inherit;">Biopharma.</span><span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-f56070d26abd sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.74pt;">Les hypothèses utilisées pour le test de dépréciation de l'écart d’acquisition sont revues annuellement. Outre le taux<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-97a9229c706d" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-0a852e8fd4a5 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 204.01pt;">d’actualisation, les principales hypothèses utilisées en <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-ffd4131bb1bf" style="width: 20.13pt;">2024<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-8ab876615271" style="width: 72.33pt;"> sont les suivantes :<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-28e1999794c2 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 230.29pt;">le taux de croissance à l’infini des flux futurs de trésorerie est <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-80cb8603e9d8" style="width: 13.41pt;">nul <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-85f545fc1da1" style="width: 108.79pt;">pour le segment Biopharma ;<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-51947483acd4" style="width: 1.95pt;"> <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-67f62a643387 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.43pt;">Sanofi s’appuie également sur des hypothèses relatives à la probabilité de succès de ses projets de recherche et<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-8458a1a7faba" style="width: 1.95pt;"> <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-00805e1b0f4a sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 407.23pt;">développement en cours et plus généralement à sa capacité à renouveler son portefeuille à plus long terme.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-525d4bd02ea1 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.75pt;">Une comparaison entre la valeur d’utilité ainsi déterminée et la valeur nette au bilan est effectuée et fait l’objet d’analyses de<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-6ce548f1d13b" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-3c3437cf650b sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 221.67pt;">sensibilité en fonction des principaux paramètres incluant :<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-e5e4eaa20fe5 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 129.98pt;">l’évolution du taux d’actualisation ;<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-79a9e1ef1c61 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 167.12pt;">l’évolution du taux de croissance à l’infini ; et<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-4ef7eafb0ef0 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 165.81pt;">l’évolution du taux de marge opérationnelle.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-c981ddbb8aed sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.79pt;">Aucune dépréciation de l'écart d’acquisition testé ne serait à constater en cas d’évolution raisonnablement possible des<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-f3d00783b17f" style="width: 1.95pt;"> <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-d3d92bf603d1 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 89.8pt;">hypothèses utilisées en <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-861c9a431090" style="width: 20.13pt;">2024<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-35ec47ca2bb0" style="width: 1.99pt;">.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-c56f7fd4ef17 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 332.12pt;">Aucune dépréciation n’a été constatée sur les écarts d’acquisition au titre des exercices <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b784274b298b" style="width: 20.13pt;">2024<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-37e3bf9f6df2" style="width: 3.94pt;">, <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-59430056abe4" style="width: 19.86pt;">2023<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-81ab899e79f9" style="width: 11.73pt;"> et <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-dbb2687581ce" style="width: 19.75pt;">2022<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-6bfeb0c49ca3" style="width: 1.99pt;">.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-faf7ad67cbab sizeStyle-d24d8708" style="font-size: 12pt;"><span class="fidelity charStyle-449e0599 positionStyle-359429408c7f">Autres actifs incorporels<span style="display: inline-block; height: 8pt;"></span><span id="ia396492aecb8428b9adf94e25c90cfc6"></span></span></div><div class="positionStyle-0ac6672e5bcc sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.78pt;">Quand un indicateur de dépréciation a été identifié pour un actif, un calcul de la valeur d’utilité est effectué, fondé sur les<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-ba26ae2e4557" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-2190e226507d sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.86pt;">prévisions de flux futurs de trésorerie après impôts de cet actif actualisés avec un taux après impôts. Dans le cadre des tests de<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-7987d75c6f28" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-4f883fef7fef sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.73pt;">dépréciation, les flux financiers d’impôts liés à cet actif sont déterminés en fonction d’un taux notionnel d’impôts, qui intègre<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-a3a6a2e27b8e" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-8ff652f42fce sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.73pt;">l’avantage fiscal notionnel qui résulterait de l’amortissement de cet actif incorporel en considérant sa valeur d’utilité comme sa<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-a3a6a2e27b8e" style="width: 1.95pt;"> <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-7ae7d16e2cc0 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.72pt;">base fiscale amortissable. L’utilisation de taux d’actualisation après impôts appliqués à des flux de trésorerie après impôts conduit<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-268e076fc9e6" style="width: 1.95pt;"> <span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-9ec990d86568 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.71pt;">à la détermination de valeurs d’utilité identiques à celles obtenues en utilisant des taux avant impôts appliqués à des flux de<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-a2dd07f22b42" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-8c3cab5a0d58 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 90.61pt;">trésorerie non fiscalisés.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-c004e188cc5d sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 188.43pt;">Les taux d’actualisation après impôts utilisés en <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-0d8b50eae990" style="width: 20.13pt;">2024<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-d3de993bed43" style="width: 281.2pt;"> pour les tests des autres actifs incorporels sont dérivés du coût moyen<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b0eda31a39ad" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-e611ed40eee1 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.76pt;">pondéré du capital de Sanofi et ajustés en fonction des risques spécifiques des pays et des activités, représentant des taux<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b0eda31a39ad" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-762c8fab7cb9 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 160.47pt;">d’actualisation après impôts compris entre<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-917b537f3134" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-f9848803192b" style="width: 24.54pt;">7,25 %<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-466bb7e30e2b" style="width: 11.73pt;"> et <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-511f7036b347" style="width: 25.2pt;">8,25 %<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-488da7e2e012" style="width: 1.99pt;">.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div><div class="positionStyle-86dd0b40af6c sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.85pt;">Dans la plupart des cas, il n’existe pas de données de marché permettant de déterminer la juste valeur nette des frais de cession<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-f0df506b3533" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-f45ee1c1b8e1 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.81pt;">autrement que par la réalisation d'une estimation similaire des flux futurs de trésorerie. Par conséquent, la valeur recouvrable est<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-6f03bf04cd80" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-3c7ad64cf834 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.75pt;">en substance égale à la valeur d’utilité. Les estimations utilisées pour déterminer la valeur d’utilité sont sensibles aux hypothèses<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-6ce548f1d13b" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-6b30290dfcb2 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.84pt;">spécifiques à la nature de l’actif et aux activités de Sanofi. Hormis le taux d’actualisation, les principales hypothèses utilisées<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-adb79b8db2ca" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-b82829080627 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 11.48pt;">en <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-10fe781007a0" style="width: 20.13pt;">2024<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-cca757120b7f" style="width: 48.15pt;"> portent sur :<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-32c2198a842d sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 141.64pt;">les prévisions à moyen et long terme ;<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-435836fe79e7 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 233.98pt;">les taux de croissance à l’infini ou d’attrition le cas échéant ; et<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-249a56ac7ceb sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 293.62pt;">la probabilité de succès des projets de recherche et développement en cours.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-a0df64a81e48 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 477.91pt;">Les hypothèses utilisées pour la réalisation des tests de dépréciation des actifs incorporels sont revues au moins annuellement.<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-d8d52527996b sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 83.41pt;">Au titre des exercices <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-31db6cec96b3" style="width: 19.75pt;">2022<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-45b234153b5e" style="width: 8.57pt;"> à <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-815eaa0c6462" style="width: 20.13pt;">2024<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-2b6b07b75f27" style="width: 357.87pt;">, les résultats des tests de dépréciation des autres actifs incorporels (hors logiciels) ont conduit<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-a3a6a2e27b8e" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-27984b5b44ad sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 183.72pt;">à enregistrer les dépréciations nettes suivantes<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-d6cdbf736f5e" style="width: 306.08pt;"> (le tableau présente sur l'ensemble des périodes l'ensemble des dépréciations<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b4332b3a566c" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-2417d5e9c56b sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 24.27pt;">nettes<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-e035806b39ef" style="width: 164.92pt;"> du périmètre du Groupe y compris Opella) :<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-b5785da03df5 sizeStyle-d24d8708" style="text-align: justify; text-align-last: var(--justify);"><div class="sizeStyle-616d3a2f wrapperStyle-73a0c67b positionStyle-707305367927"><div><table style="border-collapse: collapse; display: inline-table; font-size: initial; padding: 0; table-layout: fixed; width: 100%;"><tbody><tr style="height: 0;"><td colspan="1" rowspan="1" style="padding: 0; width: 280.5pt;"></td><td colspan="1" rowspan="1" style="padding: 0; width: 69.75pt;"></td><td colspan="1" rowspan="1" style="padding: 0; width: 69.75pt;"></td><td colspan="1" rowspan="1" style="padding: 0; width: 69.75pt;"></td></tr><tr style="height: 12.75pt;"><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-60518f7f69ad sizeStyle-72f36bb9"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-0f056a23"><span class="fidelity charStyle-0bc45b3b positionStyle-401731c6bffc">(en millions d’euros)<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="background-color: #e7e7e8; border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-ee88eebb5c11 sizeStyle-14da2a89"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-8f888f17"><span class="fidelity charStyle-748c885f positionStyle-bf75fd866d18">2024<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-01c178433f67 sizeStyle-14da2a89"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-8f888f17"><span class="fidelity charStyle-748c885f positionStyle-e68b04e2dd04">2023<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-d14f86ed5dba sizeStyle-14da2a89"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-8f888f17"><span class="fidelity charStyle-748c885f positionStyle-94400a8bce7e">2022<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td></tr><tr style="height: 12.75pt;"><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-653232dc9838 sizeStyle-72f36bb9"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-0f056a23"><span class="fidelity charStyle-748c885f positionStyle-401731c6bffc">Dépréciations nettes des reprises sur autres actifs incorporels (hors logiciels)<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="background-color: #e7e7e8; border-bottom: 0.5pt solid #23004c; border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-f1a731c8e8ae sizeStyle-14da2a89"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-8f888f17"><span class="fidelity charStyle-748c885f"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 51.63pt;"></span></span><span class="positionStyle-78a196be88ce">265<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-66d8b00147f1 sizeStyle-14da2a89"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-8f888f17"><span class="fidelity charStyle-748c885f"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 51.81pt;"></span></span><span class="positionStyle-90463c7dad1c">932<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-4cd1de1dd8c2 sizeStyle-14da2a89"><div><div class="positionStyle-a9eaf0b68c64 sizeStyle-8f888f17"><span class="fidelity charStyle-748c885f"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 49.09pt;"></span></span><span class="positionStyle-59e754313d11">(454)<span style="display: inline-block; height: 5.6pt;"></span></span></span></div></div></div></td></tr><tr style="height: 12pt;"><td colspan="1" rowspan="1" style="border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-1e2ac2c8d613 sizeStyle-c067d249"><div><div class="positionStyle-83963ec70848 sizeStyle-0f056a23"><span class="fidelity charStyle-0bc45b3b positionStyle-401731c6bffc">Produits commercialisés<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="background-color: #e7e7e8; border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-e46cecd7a633 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 51.94pt;"></span></span><span class="positionStyle-728ce798f3b0">(167)<span style="display: inline-block; height: 5.6pt; width: 0.11pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-9abc1db9c149 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 57.15pt;"></span></span><span class="positionStyle-82cfb5d98e52">—<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-top: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-3fea055f5bf0 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 47.77pt;"></span></span><span class="positionStyle-50593a4b0d43">(1 561)<span style="display: inline-block; height: 5.6pt; width: 0.11pt;"></span></span></span></div></div></div></td></tr><tr style="height: 12pt;"><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-30d7c68b7f73 sizeStyle-c067d249"><div><div class="positionStyle-83963ec70848 sizeStyle-0f056a23"><span class="fidelity charStyle-e377bace positionStyle-b3b2997de1f2">Biopharma <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-9fa74a88 positionStyle-e9a3c23866a6">(a)<span style="display: inline-block; height: 3.6399999999999997pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="background-color: #e7e7e8; padding: 0;"><div class="positionStyle-ca0710eda980 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-c27d5888"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 51.94pt;"></span></span><span class="positionStyle-728ce798f3b0">(167)<span style="display: inline-block; height: 5.6pt; width: 0.11pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-a819b1efadc0 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-c27d5888"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 57.15pt;"></span></span><span class="positionStyle-82cfb5d98e52">—<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-3073f2e1c094 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-c27d5888"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 46.06pt;"></span></span><span class="positionStyle-eaa544343dd3">(1 526)<span style="display: inline-block; height: 5.6pt; width: 0.11pt;"></span></span></span></div></div></div></td></tr><tr style="height: 12pt;"><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-1f50fc613f64 sizeStyle-c067d249"><div><div class="positionStyle-83963ec70848 sizeStyle-0f056a23"><span class="fidelity charStyle-e377bace positionStyle-b3b2997de1f2">Opella<span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="background-color: #e7e7e8; padding: 0;"><div class="positionStyle-8d49f88e3f14 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-c27d5888"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 57.15pt;"></span></span><span class="positionStyle-82cfb5d98e52">—<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-3a188f3588f6 sizeStyle-577d904f"><div><div class="positionStyle-90a57c581c95 sizeStyle-8f888f17"><span class="fidelity charStyle-c27d5888"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 57.15pt;"></span></span><span class="positionStyle-82cfb5d98e52">—<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-0061fa649a33 sizeStyle-577d904f"><div><div class="positionStyle-90a57c581c95 sizeStyle-8f888f17"><span class="fidelity charStyle-c27d5888"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 54pt;"></span></span><span class="positionStyle-297cdbd2c11c">(35)<span style="display: inline-block; height: 5.6pt; width: 0.11pt;"></span></span></span></div></div></div></td></tr><tr style="height: 12pt;"><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-12e90b30311d sizeStyle-c067d249"><div><div class="positionStyle-83963ec70848 sizeStyle-0f056a23"><span class="fidelity charStyle-956c0b7b positionStyle-401731c6bffc">Projets de recherche et développement et Plateformes technologiques <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-3c231de9 positionStyle-e78e34a121ff">(b) (c) (d)<span style="display: inline-block; height: 3.6399999999999997pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="background-color: #e7e7e8; padding: 0;"><div class="positionStyle-28985a8a9279 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 53.71pt;"></span></span><span class="positionStyle-a250c731234c">415<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-7dd621f5b9b4 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 51.45pt;"></span></span><span class="positionStyle-1ff4d0569714">896<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="padding: 0;"><div class="positionStyle-0351c91eabe5 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 49.9pt;"></span></span><span class="positionStyle-eaacfd769d5c">1 107<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td></tr><tr style="height: 12pt;"><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-af6a9f86ba27 sizeStyle-c067d249"><div><div class="positionStyle-83963ec70848 sizeStyle-0f056a23"><span class="fidelity charStyle-956c0b7b positionStyle-401731c6bffc">Autres<span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div></td><td colspan="1" rowspan="1" style="background-color: #e7e7e8; border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-7f43ac204972 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 58.29pt;"></span></span><span class="positionStyle-2644f435aa7c">17<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-c433e04e7c4c sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 55.93pt;"></span></span><span class="positionStyle-b98dbe94ff14">36<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td><td colspan="1" rowspan="1" style="border-bottom: 0.5pt solid #23004c; padding: 0;"><div class="positionStyle-6b13cf4d5140 sizeStyle-577d904f"><div><div class="positionStyle-83963ec70848 sizeStyle-8f888f17"><span class="fidelity charStyle-0bc45b3b"><span class="positionStyle-401731c6bffc"><span style="display: inline-block; height: 5.6pt; width: 57.15pt;"></span></span><span class="positionStyle-82cfb5d98e52">—<span style="display: inline-block; height: 5.6pt; width: 2.22pt;"></span></span></span></div></div></div></td></tr></tbody></table></div></div></div><div class="positionStyle-bc8c6ed1a6f7 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207"><span class="positionStyle-cf2ad5ffba18" style="width: 8.36pt;">(a)<span style="display: inline-block; height: 5.6pt; width: 5.15pt;"></span></span><span class="positionStyle-7aa89c0c0bce" style="width: 224.94pt;">Au 31 décembre 2024, ce montant concerne la reprise d’un montant de <span style="display: inline-block; height: 5.6pt;"></span></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-86be94b77628" style="width: 10.1pt;">167<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-886cc4826366" style="width: 204.94pt;"> millions d’euros constatée dans le cadre de la cession d'Enjaymo.<span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-81c8081c36b5 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-359429408c7f" style="width: 311.99pt;"> Au 31 décembre 2022, ces montants incluent principalement une reprise de dépréciation de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-b2156610c5f7" style="width: 16.77pt;">2 154<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-c169c31f3bd8" style="width: 160.87pt;"> millions d’euros sur les actifs Eloctate et BIVV001<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-ad5cc74ad3d2" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-33da2f2efe8b sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 167.7pt;">appartenant à la franchise Eloctate (respectivement <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-4a42ee88c4b2" style="width: 16.22pt;">1 554<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-35dea5d5f038" style="width: 146.94pt;"> millions d’euros en produits commercialisés et <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-07a79799f3cd" style="width: 13.44pt;">600<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-cdf473e58747" style="width: 134.2pt;"> millions d'euros en projets de recherche et<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-be0d7b939f17" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-07c4d923cd50 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 478.43pt;">développement). En 2019, l’entrée de produits concurrents d’Eloctate avait donné lieu à la mise à jour des perspectives de vente des produits de la<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-8458a1a7faba" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-1797ef14c2b9 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 345.41pt;">franchise et conduit à l’enregistrement d’une perte de valeur des actifs correspondants pour un montant de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-0974604c1dfd" style="width: 9.76pt;">2,8<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-272ec1c7368f" style="width: 123.29pt;"> milliards d’euros. Cette reprise s’inscrit<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-b4332b3a566c" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-151f81e343da sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 478.43pt;">dans le contexte de l’approbation par la FDA, le 22 février 2023, de la demande d’enregistrement d’ALTUVIIIO (nom commercial d’efanesoctocog alpha,<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-8458a1a7faba" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-9738ca91dd73 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 166.5pt;">correspondant au projet BIVV001), déposée en 2022.<span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-4d04ad91f2f8 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207"><span class="positionStyle-359429408c7f" style="width: 8.42pt;">(b)<span style="display: inline-block; height: 5.6pt; width: 2.92pt;"></span></span><span class="positionStyle-4855c92d689a" style="width: 476.12pt;">Au 31 décembre 2024, le suivi des indicateurs de perte de valeur des autres actifs incorporels a conduit à enregistrer une dépréciation nette d’un <span style="display: inline-block; height: 5.6pt; width: 2.38pt;"></span></span></span></div><div class="positionStyle-9ebcbb520b68 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 38.64pt;">montant de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-962e561b427f" style="width: 10.44pt;">415<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-8928235aec6d" style="width: 186.6pt;"> millions d’euros incluant (i) des charges de dépréciation de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-0527b71d4795" style="width: 13.04pt;">640<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-74ab013b560e" style="width: 229.79pt;"> millions d’euros sur divers projets de recherche et développement - dont<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-f0df506b3533" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-06294deff557 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 48.12pt;">une charge de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-ecd4e5719e8b" style="width: 12.11pt;">239<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-4387f16e9f81" style="width: 418.25pt;"> millions d’euros consécutive à la décision d’arrêt de l’essai clinique de phase 3 d’un candidat vaccin contre les souches pathogènes<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-0fbf97140a49" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-f2aaa39566d7 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 334.37pt;">extra-intestinales d’E.coli, intervenue en février 2025 - et (ii) une reprise de dépréciation d’un montant de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-a0e9f22ef824" style="width: 11.84pt;">225<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-d3196036c482" style="width: 132.19pt;"> millions d’euros enregistrée dans le cadre<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-97a9229c706d" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-650493bcf1ae sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 170.96pt;">de la cession de la plateforme technologique ProXTen.<span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-d6008617c9d3 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207"><span class="positionStyle-359429408c7f" style="width: 7.98pt;">(c)<span style="display: inline-block; height: 5.6pt; width: 3.36pt;"></span></span><span class="positionStyle-4855c92d689a" style="width: 263.19pt;">Au 31 décembre 2023, ces montants incluent principalement une dépréciation de <span style="display: inline-block; height: 5.6pt;"></span></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-9d785fbb8fa4" style="width: 12.18pt;">833<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-e19d5d3412b2" style="width: 203.08pt;"> millions d’euros reflétant l’impact de la décision stratégique de<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-f3d00783b17f" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-d0fd3f0f9374 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 464.55pt;">dépriorisation de certains programmes de Recherche et Développement liés notamment aux plateformes technologiques de cellules NK et ProXTen.<span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-7023a022b7e1 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207"><span class="positionStyle-359429408c7f" style="width: 8.42pt;">(d)<span style="display: inline-block; height: 5.6pt; width: 2.92pt;"></span></span><span class="positionStyle-4855c92d689a" style="width: 179.04pt;">Au 31 décembre 2022, ce montant inclut principalement :<span style="display: inline-block; height: 5.6pt;"></span></span></span></div><div class="positionStyle-bb6b0c2730fa sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 117.41pt;">- une dépréciation d'un montant de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-67acc3ee9448" style="width: 16.94pt;">1 586<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-63be32d8499d" style="width: 344.1pt;"> millions d'euros portant sur le projet en développement SAR444245 (interleukine-2 non-alpha), enregistrée<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-f3d00783b17f" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-8ba96848e220 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-f37c12ed05b4" style="width: 435.39pt;">suite à la mise à jour des projections des flux de trésorerie attendus, en raison d'évolutions défavorables de ses perspectives de lancement ;<span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-f707c2670463 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 3.15pt;">-<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-b9bdb0d41cd6" style="width: 91.85pt;"> une reprise d’un montant de <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-050fdf2e5865" style="width: 13.44pt;">600<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-1af88aaad23e" style="width: 164.64pt;"> millions d’euros sur le projet BIVV001 (voir ci-dessus)<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-256faca6758c" style="width: 1.65pt;">.<span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-ad832f011bab sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.69pt;">En application de la norme IFRS5, les autres actifs incorporels relatifs à l'activité Opella ont été mesurés conformément à la norme<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-8137a6ec08a7" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-50c12e5bb4bb sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.85pt;">IAS 36 immédiatement avant leur reclassement en actifs destinés à être cédés. Cette évaluation n'a pas conduit à enregistrer de<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-f0df506b3533" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-5ca635bc7f1f sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 146.07pt;">dépréciation de leur valeur comptable.<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-8a97ff64a56c" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-8e2803cf9685 sizeStyle-d24d8708" style="font-size: 12pt;"><span class="fidelity charStyle-449e0599 positionStyle-359429408c7f">Actifs corporels<span style="display: inline-block; height: 8pt;"></span><span id="i7d84e14f5729489d9607060c92453704"></span></span></div><div class="positionStyle-d08736615695 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 319.97pt;">Le montant des dépréciations relatives aux actifs corporels est présenté en note D.3.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-4ff5f516a4d9 sizeStyle-d24d8708" style="font-size: 12pt;"><span class="fidelity charStyle-449e0599 positionStyle-359429408c7f">Risques et opportunités liés au changement climatique<span style="display: inline-block; height: 8pt;"></span><span id="i0fde9098c3434973b0f7e53aebc17b7b"></span></span></div><div class="positionStyle-e7dccf84e0ce sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 110.81pt;">Sanofi a identifié plusieurs <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-27680c46fc98" style="width: 29.62pt;">scenarii<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-c75c9c1d6db8" style="width: 349.4pt;"> plausibles afin de mesurer les risques et opportunités liés au changement climatique<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-48a33b297368" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-dc1081e40091 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 267.66pt;">susceptibles d’impacter les activités du Groupe à moyen et long terme.<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-c493724c93b4 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 66.19pt;">Ceux-ci incluent :<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-f383e58d286a sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 15pt;">un <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-2431bf91e24e" style="width: 32.62pt;">scenario<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-ef2696a90e6b" style="width: 112.58pt;"> de remédiation agressive <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-ee27a81ab9c8" style="width: 90.85pt;">(Aggressive Mitigation)<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-1f9dff518f88" style="width: 227.44pt;">, basé sur une collaboration mondiale visant à réduire<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-8e59220fdeb3" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-9a461a7ee8ae sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.42pt;">immédiatement les émissions pour atteindre les objectifs de l’Accord de Paris (limitation du réchauffement à 1,5 °C au-dessus<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b0eda31a39ad" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-3b7c5ca74aba sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 156.72pt;">des niveaux de l’ère préindustrielle). Ce <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-2072efb3c9c4" style="width: 32.62pt;">scenario<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-900e8f880be0" style="width: 289.08pt;">, qui engendre des risques de transition à une économie moins carbonée,<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b0eda31a39ad" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-31aa7b68e6fd sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.47pt;">implique des changements significatifs ayant trait notamment aux politiques, technologies, marchés et aspects juridiques de<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-048c0de60422" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-1b321a58836c sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 306.24pt;">son activité, dans le but d’atteindre ces objectifs de remédiation et d’adaptation ;<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-b166bb766954 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 11.86pt;">un <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-58723037a48e" style="width: 32.62pt;">scenario<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-d8f3aba089ce" style="width: 183.56pt;"> basé sur l’absence d’actions relatives au climat, <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-1935dda104a4" style="width: 70.08pt;">No Climate Action<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-811c8df62802" style="width: 180.34pt;">, conduisant à un réchauffement global de 4 °C<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b4332b3a566c" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-0a75ae8231ae sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.4pt;">au-dessus des niveaux de l’ère préindustrielle en 2100, qui induit des risques physiques ponctuels résultant des modifications<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-97a9229c706d" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-47e2d350715a sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.4pt;">du climat et des évolutions à long terme des tendances climatiques, avec des conséquences financières potentielles résultant<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-97a9229c706d" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-0e4979322276 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.43pt;">des dommages directs aux biens ou des dommages indirects liés à l’interruption des chaînes de distribution logistique, à des<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-8458a1a7faba" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-fea4be371dda sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.46pt;">modifications dans la disponibilité des ressources en eau, dans l’approvisionnement ou la qualités des ressources, dans la<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b4332b3a566c" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-8bc3b01fabe0 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.48pt;">sécurité alimentaire et des modifications des températures extrêmes impactant les installations, les opérations, la distribution,<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-0fbf97140a49" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-ce63b8e42675 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 209.69pt;">les besoins en transport ou la sécurité des employés ; et<span style="display: inline-block; height: 6.8pt;"></span></span></div></div><div class="positionStyle-86dd0b40af6c sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-8b512e93 positionStyle-359429408c7f" style="width: 2.9pt;">•<span class="fidelity positionStyle-b7726dbb1335"> </span><span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 12.34pt;">un <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-9aa98d16a200" style="width: 32.62pt;">scenario<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-289bae67caa0" style="width: 39.56pt;"> probable <span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-9b6b0f47 positionStyle-29b79a932aad" style="width: 48.4pt;">(Most Likely)<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-4373f4c2922e" style="width: 345.49pt;">, incluant des efforts régionaux parcellaires destinés à initier une réduction des émissions,<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-6ce548f1d13b" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-f45ee1c1b8e1 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 478.46pt;">mais insuffisants pour atteindre les objectifs de l’Accord de Paris (les émissions continuent d’augmenter quoiqu’à un rythme<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-b4332b3a566c" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-3c7ad64cf834 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-4855c92d689a" style="width: 257pt;">réduit, conduisant à une augmentation des températures de 2,8 °C).<span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-012a961a24cb sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 489.77pt;">L’importance et la probabilité d’occurrence de ces risques ont été mesurés et n’ont pas conduit à identifier d’effets significatifs<span style="display: inline-block; height: 6.8pt;"></span></span><span class="fidelity charStyle-4697d878 positionStyle-8458a1a7faba" style="width: 1.95pt;"> <span style="display: inline-block; height: 6.8pt;"></span></span></div><div class="positionStyle-a4f80aaea193 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-4697d878 positionStyle-359429408c7f" style="width: 289.38pt;">pouvant générer un risque de dépréciation sur les actifs des UGT du Groupe.<span style="display: inline-block; height: 6.8pt;"></span></span></div> != <div class="positionStyle-6163b486fbe6"><div style="width: 489pt;"><div class="positionStyle-36d194b72471 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-e4354d28"><span class="positionStyle-b58d73c6e12d" style="width: 4.15pt;">(1)<span style="display: inline-block; height: 3.6399999999999997pt; width: 7.19pt;"></span></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 331.26pt;">Cette section permet de répondre au point de donnée [ESRS E1, E1-9 Para. 15] inclus dans la section « <span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-931a689d497e" style="width: 147.06pt;">3.2.1.1. Stratégie climatique et gestion des IRO<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-ebe41e51ce20" style="width: 1.61pt;"> <span style="display: inline-block; height: 5.6pt;"></span></span></div><div class="positionStyle-d50f7f979a73 sizeStyle-d24d8708" style="font-size: 12pt; text-align: justify; text-align-last: var(--justify);"><span class="fidelity charStyle-1dfc5207 positionStyle-4855c92d689a" style="width: 49.87pt;">correspondants<span style="display: inline-block; height: 5.6pt;"></span></span><span class="fidelity charStyle-1dfc5207 positionStyle-0c2fabeb8813" style="width: 7.69pt;"> ».<span style="display: inline-block; height: 5.6pt;"></span></span></div></div></div> please review selected entries. |
© 2021-23 XBRL All Rights Reserved.